BSX May 2024 70.000 call
- PR Newswire
MODULAR ATP Study of the mCRM™ System Meets Primary Safety and Efficacy Endpoints
Boston Scientific Corporation (NYSE: BSX) today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRM™ System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System and the EMPOWER™ Leadless Pacemaker (LP). As components of the mCRM System, the devices are designed to work together wirelessly to coordinate painless intracardiac anti-tachycardia pacing (ATP) therap
- Zacks
Veeva's (VEEV) Vault Basics to Boost Efficiency for Biotechs
Veeva (VEEV) announces the availability of Vault Basics for biotechs, which aims to deliver complete and pre-validated solutions for expanding businesses.
- Zacks
AxoGen (AXGN) Initiates BLA Submission for Avance Nerve Graft
AxoGen (AXGN) starts the process of BLA submission to the FDA for the approval of its Avance Nerve Graft.
